Related Experiment Video
Updated: Aug 25, 2026
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug response assay system in a microchip using human hepatoma cells
Yuki Tanaka1, Kiichi Sato, Masayuki Yamato
1Department of Applied Chemistry, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-8656, Japan.
Abstract:
A microchip-based cell response assay system to an anticancer agent was developed. The hepatoma cell line HepG2 was used to assess the effects of an anticancer agent, doxorubicin. The required cell number was reduced by two orders, and the observation of the time course of cell response became possible. The system clearly showed that treatment with higher doses of the drug or longer exposure times gave more effects to cells. The possibilities of novel drug response studies or toxicity assay system were demonstrated.
Insights
A novel microchip assay system effectively measures cancer cell response to drugs like doxorubicin. This system reduces cell usage and allows detailed observation of drug effects over time.
Area of Science:
- Biomedical Engineering
- Cell Biology
- Pharmacology
Background:
- Assessing anticancer drug efficacy requires sensitive and efficient cell-based assays.
- Traditional methods often demand large cell numbers and lack temporal resolution.
- Developing advanced systems is crucial for personalized medicine and drug discovery.
Purpose of the Study:
- To develop a microchip-based assay system for evaluating cellular responses to anticancer agents.
- To utilize the hepatoma cell line HepG2 for assessing doxorubicin's effects.
- To demonstrate the system's capability for high-throughput and time-course drug response analysis.
Main Methods:
- Development of a microchip platform for cell culture and drug treatment.
- Utilizing the HepG2 hepatoma cell line for drug sensitivity testing.
- Quantitative analysis of cell response to varying doxorubicin concentrations and exposure durations.
Main Results:
- The microchip system significantly reduced the required number of HepG2 cells by two orders of magnitude.
- Enabled real-time monitoring of the time course of cellular response to doxorubicin.
- Demonstrated a clear dose-dependent and time-dependent effect of doxorubicin on HepG2 cells.
Conclusions:
- The developed microchip assay system provides a sensitive and efficient platform for anticancer drug evaluation.
- This technology facilitates novel drug response studies and toxicity assessments.
- The system holds potential for optimizing cancer treatment strategies and accelerating drug development.
